While blood testing for levels of carcinoembryonic antigen (CEA) is standard clinical practice for postresection monitoring of CRC patients, CEA has limited value due to poor sensitivity for residual disease and non‐neoplastic factors (such as smoking) adversely affecting assay specificity [4, 5, 6, 7]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.